<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_SYSU-MEDICINE_Results skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:SYSU-MEDICINE/Results</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="container-fluid"><DIV class="navbar-header"><BUTTON type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false"><SPAN class="sr-only">Toggle navigation</SPAN></BUTTON><A class="navbar-brand" href="https://2016.igem.org/Team:SYSU-MEDICINE">SYSU-MEDICINE</A></DIV><DIV class="collapse navbar-collapse" id="bs-example-navbar-collapse-1"><UL class="nav navbar-nav navbar-right"><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE">HOME</A></LI><LI class="dropdown active"><A href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">PROJECT</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Description">Description</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Results">Results</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Protocol">Protocol</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Notebook">Notebook</A></LI><LI class="dropdown third-level-menu"><A href="#" class="dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">For Judgement </A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Proof">Proof of Concept</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Demonstrate">Demonstrate</A></LI></UL><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">HUMAN PRACTICES</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Our_Story">Our Story</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview">Interview</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Ethics">Ethics</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Legislation">Legislation</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Products">Products</A></LI><LI class="dropdown third-level-menu"><A href="#" class="dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">For Judgement </A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/HP/Silver">Silver</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/HP/Gold">Gold</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Integrated_Practices">Integrated Practices</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Engagement">Engagement</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Modeling">MODELING</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">TEAM</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Team">Team</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Attributions">Attributions</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Collaborations">Collaborations</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">PARTS</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Parts">Parts</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Basic_Part">Basic Parts</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Composite_Part">Composite Parts</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Part_Collection">Part Collection</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Safety">SAFETY</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Judging">JUDGING</A></LI></DIV></DIV><DIV class="jumbotron"><DIV class="my-content"><H1 align="center">Results</H1></DIV></DIV><DIV class="jumbotron" id="content"><DIV class="mynav"><OL><LI><A href="#Results1">Major Achievements</A></LI><LI><A href="#Results2">Details</A></LI></OL></DIV><DIV class="my-content"><H2 id="Results1">Major achievements:</H2><P><A href="#Results1.1">1. Our modified MSCs still remained their own characteristics.</A><A href="#Results1.2">2. CCR7/CXCR4/CXCR5 were successfully overexpressed on our modified MSCs.</A><A href="#Results1.3">3. Chemotaxis of our engineered MSCs improved.</A><A href="#Results1.4">4. Marking proteins (eGFP/dTomato) worked.</A><A href="#Results1.5">5. Therapeutic effects of our engineered MSCs for IBD (inflammatory bowel disease) improved.</A><A href="#Results1.6">6. Therapeutic effects of our engineered MSCs for DTH (delayed type hypersensitivity) improved.</A><A href="#Results1.7">7. The switch element worked.</A></P><H2 id="Results2">Details: </H2><P><B id="Results1.1"><BIG>1. Our modified MSCs still remained their own characteristics. </BIG></B></P><P><SPAN class="note" style="text-align: center">
                Figure 2.1.1</SPAN></P><P><SPAN class="note" style="text-align: center">
                Figure 2.1.2</SPAN></P><P>
            Our modified MSCs were positive for CD105, CD90, CD29 and CD73 and negative for CD34 (Figure 2.1.1 A-E), and were able to differentiate to osteoblasts, adipocytes, and chondroblasts under standard in vitro differentiating conditions (Figure 2.1.2 F-K). (Meet the standard of International Society for Cellular Therapy (ISCT))<B id="Results1.2"><BIG>2. CCR7/CXCR4/CXCR5 were successfully overexpressed on our modified MSCs.</BIG></B></P><TABLE><TBODY><TR><TD style="text-align: center"><SPAN class="note">
                        Figure 2.2.1</SPAN></TD><TD style="text-align: center"><SPAN class="note">
                        Figure 2.2.2</SPAN></TD><TD style="text-align: center"><SPAN class="note">
                        Figure 2.2.3</SPAN></TD></TR></TBODY></TABLE><P><SPAN class="note" style="text-align: center">
                Figure 2.2.4</SPAN>
            mRNA and protein levels of CCR7, CXCR4 and CXCR5 of MSCs and our modified MSCs (EF-1α-CCR7, EF-1α-CXCR4-T2A-Luciferase-IRES-eGFP, EF-1α-CXCR5-IRES-eGFP, respectively) (BBa_K1993001, BBa_K1993009, BBa_K1993005, respectively) were semi-quantified and detected by qPCR and western blot, respectively. mRNA and protein levels of CCR7, CXCR4 and CXCR5 all elevated in our modified MSCs.<B id="Results1.3"><BIG>3. Chemotaxis of our engineered MSCs improved. </BIG></B></P><TABLE><TBODY><TR><TD style="text-align: center"><SPAN class="note">
                        Figure 2.3.1</SPAN></TD><TD style="text-align: center"><SPAN class="note">
                        Figure 2.3.2</SPAN></TD><TD style="text-align: center"><SPAN class="note">
                        Figure 2.3.3</SPAN></TD></TR></TBODY></TABLE><P><SPAN class="note" style="text-align: center">
                Figure 2.3.4</SPAN>
            Chemotaxis of our engineered MSCs (EF-1α-CCR7, EF-1α-CXCR4-T2A-Luciferase-IRES-eGFP, EF-1α-CXCR5-IRES-eGFP, respectively) (BBa_K1993001, BBa_K1993009, BBa_K1993005, respectively) were examined against CCL19, CXCL12 and CXCL13, respectively. Results were reported as number of cells migrated. Chemotaxis capacity of our engineered MSCs all improved.<B id="Results1.4"><BIG>4. Marking proteins (eGFP/dTomato) worked. </BIG></B><SPAN class="note" style="text-align: center">
                Figure 2.4.1</SPAN><B>4.1</B> 2 days later, after transduction into 293FT cells, marking proteins (eGFP/dTomato) expressed.
            Figure A: 293FT cells (BBa_K1993011: EF-1α-CXCR4-IRES-Luciferase-T2A-dTomato-T2A- hFTH)
            Figure B: 293FT cells (BBa_K1993005: EF-1α-CXCR5-IRES-eGFP)
            Figure C: 293FT cells (BBa_K1993009: EF-1α-CXCR4-T2A-Luciferase-IRES-eGFP)
            Figure D: 293FT cells (BBa_K1993008: EF-1α-Luciferase-IRES-eGFP) <SPAN class="note" style="text-align: center">    Figure 2.4.2</SPAN><B>4.2</B> 4 days later, after transduction into MSCs, marking proteins (eGFP/dTomato) expressed.
            Figure A: MSCs (BBa_K1993011: EF-1α-CXCR4-IRES-Luciferase-T2A-dTomato-T2A-hFTH)
            Figure B: MSCs (BBa_K1993005: EF-1α-CXCR5-IRES-eGFP)
            Figure C: MSCs (BBa_K1993009: EF-1α-CXCR4-T2A-Luciferase-IRES-eGFP)
            Figure D: MSCs (BBa_K1993008: EF-1α-Luciferase-IRES-eGFP) <SPAN class="note" style="text-align: center">
                Figure 2.4.3</SPAN><B>4.3</B> After intraperitoneal injection of Luciferin, MSCs engineered with GFP and Luciferase were administrated intravenously to caudal vein. Oxidized Luciferin was observed under IVIS spectrum system. As a result, mice administered with engineered MSCs （BBa_K1993008: EF-1α-Luciferase-IRES-eGFP）<B id="Results1.5"><BIG>5.Therapeutic effects of our engineered MSCs for inflammatory bowel disease(IBD) improved.</BIG></B>
            Our MSCs were modified by BBa_K1993009 (EF-1α-CXCR4-T2A-Luciferase-IRES-eGFP).</P><TABLE><TBODY><TR><TD style="text-align: center"><SPAN class="note">
                        Figure 2.5.1.1</SPAN></TD><TD style="text-align: center"><SPAN class="note">
                        Figure 2.5.1.2</SPAN></TD></TR><TR><TD style="text-align: center"><SPAN class="note">
                        Figure 2.5.1.3</SPAN></TD><TD style="text-align: center"><SPAN class="note">
                        Figure 2.5.1.4</SPAN></TD></TR></TBODY></TABLE><P><B>5.1</B> We established murine 2,4,6-trinitro benzene sulfonic acid (TNBS)-colitis (IBD animal model). After injecting with MSCs<SUP>CXCR4</SUP>, survival rate, body weight, length of colon and DAI score of IBD mice were improved significantly comparing to TNBS+MSC group and TNBS+saline group.<SPAN class="note" style="text-align: center">
                Figure 2.5.2</SPAN><B>5.2</B> Photographs of hematoxylin/eosin-stained colon cross-sections 2 days after injecting MSCs. MSCs<SUP>CXCR4</SUP> displayed better treatment efficacy than TNBS+MSC group and TNBS+saline group, characterized by their abilities to decrease leukocyte infiltration.</P><TABLE><TBODY><TR><TD style="text-align: center"><SPAN class="note">
                        Figure 2.5.3.1</SPAN></TD><TD style="text-align: center"><SPAN class="note">
                        Figure 2.5.3.2</SPAN></TD></TR><TR><TD style="text-align: center"><SPAN class="note">
                        Figure 2.5.3.3</SPAN></TD><TD style="text-align: center"><SPAN class="note">
                        Figure 2.5.3.4</SPAN></TD></TR></TBODY></TABLE><P><B>5.3</B> Colon sampling for quantitative PCR analysis. Comparing with TNBS+MSC group, levels of the anti-inflammatory cytokine (IL-10) elevated in TNBS+MSC<SUP>CXCR4</SUP> group while pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) levels decreased in TNBS+ MSC<SUP>CXCR4</SUP> group.<SPAN class="note" style="text-align: center">
                Figure 2.5.4.1</SPAN><B>5.4</B>	Under IVIS Spectrum, MSCs<SUP>CXCR4</SUP> exhibited enhanced capacities for targeted migration to the bowels in inflammatory condition in vivo.<B id="Results1.6"><BIG>6. Therapeutic effects of our engineered MSCs for delayed type hypersensitivity(DTH)) improved. </BIG></B>
            Our MSCs were modified by BBa_K1993005 (EF-1α-CXCR5-IRES-eGFP).<SPAN class="note" style="text-align: center">
                Figure 2.6.1.1</SPAN><SPAN class="note" style="text-align: center">
                Figure 2.6.1.2</SPAN><B>6.1</B> MSCs<SUP>CXCR5</SUP> infusion dramatically ameliorated DTH. MSCs<SUP>CXCR5</SUP> displayed better treatment efficacy than DTH+MSC<SUP>eGFP</SUP> group, characterized by their abilities to decrease ear thickness and leukocyte infiltration. MSCs<SUP>CXCR5</SUP> significantly attenuated DTH as early as 24 hours post-injection, and had even greater effects at 48 hours post-injection.<SPAN class="note" style="text-align: center">
                Figure 2.6.2</SPAN><B>6.2</B> Ear sampling for quantitative PCR analysis. Comparing with DTH+MSCs group, levels of the anti-inflammatory cytokines (IL-10), elevated in DTH+MSCs<SUP>CXCR5</SUP> group, while levels of pro-inflammatory cytokines (IL-4, TNF-α, IFN-γ, IL-6 and IL-17) decreased in DTH+MSCs<SUP>CXCR5</SUP> group.<SPAN class="note" style="text-align: center">
                Figure 2.6.3</SPAN><B>6.3</B> The inflamed ears were collected from each group on Day2 post-injection, and subjected to in situ immunofluorescence staining. Our results revealed that MSCs<SUP>eGFP</SUP> were almost undetectable, whereas MSCs<SUP>CXCR5</SUP> were highly accumulated in the inflamed ears of DTH mice.<B id="Results1.7"><BIG>7. The switch element worked.</BIG></B><SPAN class="note" style="text-align: center">
                Figure 2.7</SPAN>
            Transduction of our switch plasmid into MSCs. After administering TGF-β1 (7ng/mL), α-SMA was expressed and green fluorescence could be detected in MSCs (BBa_K1993014: pMSA-eGFP worked), which indicated our switch was running.</P></DIV></DIV><DIV class="jumbotron" id="jumbo-footer"><DIV class="footer-container"><DIV class="title">
            Contact us
        </DIV><DIV class="contact"><UL class="float-contact"><LI><A href="http://weibo.com/u/5999650333">
                        iGEMxSYSU-MEDICINE
                    </A></LI><LI><A href="https://www.facebook.com/IGEM-SYSU-Medicine">
                        IGEM SYSU-Medicine
                    </A></LI><LI><A href="#">
                        SYSU_MEDICINE@163.com
                    </A></LI></UL><UL class="float-contact"><LI><A href="#" data-toggle="modal" data-target="#wechatModal">
                        SYSU-MEDICINE
                    </A></LI><LI><A href="https://twitter.com/IgemSysu">
                        iGEM SYSU-MEDICINE
                    </A></LI></UL></DIV><DIV class="copyright"><DIV class="text">© 2016 SYSU-MEDICINE. All Rights Reserved.
            </DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>